Natco Pharma has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupi...

Generic molnupiravir will increase access in India and other low- and middle-income countries (LMICs), while simplifying current supply cha...

The group is all set to launch the generic Molnupiravir 200 mg capsules and it is being manufactured at its USFDA and MHRA accredited facil...

Flagging the various health concerns surrounding the Covid anti-viral drug Molnupiravir, ICMR’s Dr Balram Bhargava said that Merck’s corona...

The full treatment of Molulife (brand name) is expected to cost ₹1,400, RC Juneja, chairman of Mankind Pharma, told ET. The brand is expect...

Dr. Reddy’s Molflu will be priced at Rs. 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over 5 da...

Shares of Strides Pharma were up 2.3 per cent while those of Cipla gained 1.4 per cent. Dr Reddy’s scrip registered a gain of close to a pe...

Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection ...

Under the licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries, fo...

Drug maker Cipla said it will soon make molnupiravir capsules available at all leading pharmacies and Covid treatment centers across the co...

The recommendations have been sent to the Drug Controller General of India (DCGI), which will soon decide on their approval, people in the ...

The Subject Expert Committee (SEC) under the drug regulator of India has asked manufacturers in India to specify the category of Covid pati...

The company said it has received its clinical trial approval on May 19, 2021, from the Drug Controller General of India (DCGI) to perform a...

The Hyderabad-based firm said the first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals.

Natco Pharma on Friday said it has initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patien...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...

The development comes close on the heels of findings announced by the researchers that Molnupiravir was found effective for treating the pa...